Category Archives: Healthcare Professionals

Wilson Dental of McLean, a Veteran-owned Business Teams Up With Soldiers’ Angels to Collect Halloween Candy for Troops and Veterans

 

McLean, Virginia, 2019-Oct-30 — /EPR HEALTHCARE NEWS/ — Every year, millions of pounds of candy end up in the trash after Halloween. From over-buying, to kids collecting more than they can eat while Trick-or-Treating, candy is wasted across the country. This year, Wilson Dental of McLean is participating in a program that will help our community produce less waste after Halloween while also showing our support for our service members and veterans! Owner, Dr. Lois Wilson, is herself a Veteran who proudly served as an Army Dentist both here and overseas.

Soldiers’ Angels, a national 501(c)3 nonprofit, hosts an annual collection drive for excess Halloween candy. The organization ships the candy to deployed service members around the world for a sweet treat from home! They also utilize their “Angel” volunteers to distribute candy to veterans of all eras in VA Hospitals across the country.

Wilson Dental of McLean is proud to team up with the national organization to get our local community involved with giving back to the brave men and women who have sacrificed so much for our country. Our business has registered with Soldiers’ Angels to be an official drop-off site for Halloween candy. Once our collection drive is over, Wilson Dental of McLean will donate all collected candy to Soldiers’ Angels where it will be packaged and shipped to deployed or distributed in VA Hospitals.

“As a veteran of the US Army, I am excited to facilitate a donation for our service men and women who are deployed or currently in the hospital. I know first hand that being away from your family during joyful holidays is extremely difficult and I hope that this small token can help bring joy to those who sacrifice so much for our country.” – Dr. Wilson

The vision of Soldiers’ Angels is: May No Soldier Go Unloved. Although the gesture of handing out miniature candy bars may seem small, the impact that small gesture can have on troops and veterans is huge.

“When you are deployed to a combat zone, there are many comfort items you may go without for an extended period of time,” says Amy Palmer, President and CEO of Soldiers’ Angels. “Receiving care packages from home is a wonderful and unexpected surprise. The joy these service members get from opening a package of treats from home is immense and has a profound impact on their morale. The same can be said for veteran patients in VA Hospitals. Some patients have no family or regular visitors. When our Angel volunteers come in with treats like candy, the spirits of these patients are immediately lifted!”

Our collection drive will run from October 25th 2019 to November 18th 2019. Please call ahead before stopping by our location to drop off your candy:

Wilson Dental of McLean
1447-C Dolley Madison Blvd
McLean Virginia 22101

For more information on the program, or if you are interested in registering your business as a drop-off site, visit: www.SoldiersAngels.org/TreatsForTroops

Via EPR Network
More Healthcare press releases

First Rhenium-SCT® (Skin Cancer Therapy) treatment in Germany done by Dr. Lutz-Hendrik Holle

HANAU, Germany, 4-Oct-2019 — /EPR HEALTHCARE NEWS/ — OncoBeta®, a Medical Device Company specialized in innovative epidermal radioisotope therapies for Non-Melanocytic Skin Cancers (NMSCs), announced today, that Dr. Lutz-Hendrik Holle, Medical Director of the interregional professional association for nuclear medicine in Hanau, has accomplished the first Rhenium-SCT® (Skin Cancer Therapy) treatment in Germany. This state-of-the-art technology of local radionuclide therapy offers a painless and non-invasive treatment option for patients with basal cell carcinoma and squamous cell carcinoma (BCC and SCC) and the interregional professional association for nuclear medicine Hanau is the first center in Germany that offers the Rhenium-SCT®.

With approximately 50.000 outpatient examinations annually, the interregional professional association for nuclear medicine Hanau is one of the biggest nuclear medicine service providers in Hesse. The offered services include a variety of different modern treatment and diagnostic methods. The key argument for the expansion of the spectrum was that the Rhenium-SCT® is a new, painless and highly efficient treatment option that also delivers excellent cosmetic results. Besides being a painless alternative to other procedures, the Rhenium-SCT® also allows the treatment of numerous NMSC lesions consecutively in a single session, which was already realized during the first treatment in Hanau. This has also attracted international attention so that an American patient travelled to Hanau for the treatment.

“This therapy is particularly suitable for tumor localizations where good cosmetic results are to be achieved. The fact that the treatment is completely painless and can be performed in just one session is a great advantage”, says Dr. Lutz-Hendrik Holle, Medical Director of Nuclear Medicine in Hanau.

“We are very happy and proud to be able to offer our revolutionary treatment to patients in Germany now. The interregional professional association of nuclear medicine in Hanau is an excellent partner for NMSC patients in the fight against NMSC”, said Shannon D. Brown III, CEO and Managing Director of OncoBeta® GmbH. “Unfortunately, Germany is one of the countries that has experienced a drastic increase in newly diagnosed NMSC cases in recent years. Our highly qualified team strives to provide physicians and patients with a non-invasive and affordable solution to treat NMSC, while focusing on the needs of the patient.”

The global incidence of non-melanoma skin cancers has been drastically increasing over the past decades. Depending on the source, it is estimated that there are over 5 million non-melanoma skin cancer cases reported globally each year. In certain analyzed areas of Germany there was an increase in the incidence between the year 2005 and the year 2014 by about 30%1. To serve the increasing medical need for innovative therapies in this field and to improve the quality of patients’ lives, OncoBeta® GmbH has developed its innovative Rhenium-SCT® which only require a single application in most of the cases, applied in one single session with excellent aesthetic outcomes.

Via EPR Network
More Healthcare press releases

CoapTech and Fidmi Medical to Collaborate on Groundbreaking G-Tube Systems

Baltimore, MD, 2019-Sep-18 — /EPR HEALTHCARE NEWS/ — CoapTech LLC (Baltimore, MD) and Fidmi Medical, Ltd. (Caesarea, Israel) announced today that they will be collaborating on bringing to market a set of next-generation products for the initial placement and long-term maintenance of gastrostomy tubes (G-tubes). The collaboration between CoapTech and Fidmi will focus on integrating the company’s two technologies and expanding their collective market opportunities.

Gastrostomy tubes, which help patients receive long-term nutritional support, are typically placed endoscopically and need to be replaced every 3-6 months.

CoapTech’s PUMA-G System allows initial gastrostomy tube placement by non-surgeons/ gastroenterologists, outside of the endoscopy suite, using point-of-care ultrasound at the patient bedside. This novel approach can be performed in the ICU, emergency room, and eventually outside of the hospital setting, substantially reducing costs for tube placement.

Fidmi Medical’s innovative low-profile gastrostomy system is unique in that it can be utilized for both initial placement and replacement and has several features which make it more durable and comfortable for patients. Gastrostomy tubes very often get dislodged, clogged, or infected, and need to be replaced frequently. Fidmi’s improved low-profile gastrostomy tube is placed just like any standard PEG tube but has an easily replaceable inner tube which can be changed by patients without the need to re-enter the healthcare system for replacement procedures. This will result in fewer complications with patients’ g-tubes, therefore potentially reducing healthcare costs for payers and healthcare systems; as well as providing a substantial improvement in quality of life for patients and their caregivers.

Fidmi Medical Chairman, Lloyd Fishman, commented, “We are excited to collaborate with CoapTech in development and marketing. Both companies have developed cutting-edge technologies that will improve patient care and contribute to the ease, efficiency and confidence of clinicians’ work in the gastrostomy field.”

Dr. Steven Tropello, CoapTech’s founder and CMO said, “In combination these systems will be compatible with Push or Pull methods, be implantable in a wide variety of clinical settings, and require minimal readmission to the hospital and fewer visits to the ER. The synergy will reduce both front and back-end costs for hospitals and payers, and make care safer and more patient-centered.”

Via EPR Network
More Healthcare press releases

2019 Red Herring North America Top 100 Winner: New recognition of OncoBeta’s success in developing and providing an innovative therapy for non-melanoma skin cancer patients

Pasadena, CA, U.S.A., 6-Jul-2019 — /EPR HEALTHCARE NEWS/ — OncoBeta®, a Medical Device Company specialized in innovative epidermal radioisotope therapies for Non-Melanocytic Skin Cancers (NMSCs), announced today, that it was honored as a Red Herring Top 100 North America Award winner recognizing the continent’s most exciting and innovative private technology companies. After being recognized with the Red Herring Top 100 Europe Award earlier this year, this is now the second recognition obtained by Red Herring.

The winners, celebrated at a special awards ceremony at the Westin Pasadena hotel, have been chosen from thousands of entrants, whittled down to hundreds making the trip to California. The ceremony, led by Red Herring chairman Alex Vieux, was preceded by two days of keynote speeches, discussions and finalist presentations.

Companies were judged by industry experts, insiders and journalists on a wide variety of criteria including financial performance, innovation, business strategy, and market penetration. Winners ran the gamut of verticals, from FinTech and Marketing to Security, IoT, and many more industries.

Red Herring’s editors have been evaluating the world’s startups and tech companies for over two decades. It gives them the ability to see through the industry’s hype to pick firms that will continue on a trajectory to success. Brands such as Alibaba, Google, Kakao, Skype, Spotify, Twitter and YouTube have all been singled out in Red Herring’s storied history.

“2019’s crop of Top 100 winners has been among our most intriguing yet,” said Vieux. “North America has led the way in tech for so many years, and to see such unique, pioneering entrepreneurs and companies here in California, which is in many ways the heartland of the industry, has been a thrilling experience.”

“What has excited me most is to see so many people forging niches in high-tech and cutting edge sectors,” added Vieux. “Some of the technical wizardry and first-rate business models showcased here at the conference has been fantastic to learn about. We believe OncoBeta® embodies the drive, skill and passion on which tech thrives. OncoBeta® should be proud of its achievement – the competition was incredibly strong.”

“Being named as one of the Red Herring’s Top 100 North America award winner in addition to the Top 100 Europe is a great honor for us.” states Shannon D. Brown III, CEO of OncoBeta®. “The spirit of the award aligns perfectly with our team’s mission in the fight against non-melanocytic skin cancer (NMSC) with the Rhenium-SCT®.”

The complete list of the 2019 Red Herring North America Top 100 Winners can be found here in alphabetical order: https://www.redherring.com/2019-rhna-top100-winners/

Red Herring’s press release is available online at https://www.redherring.com/red-herring-2019-top-100-north-america-winners-press-release/

SOURCE: EuropaWire

The interregional professional association for nuclear medicine in Hanau has become the first treatment center in Germany to offer the Rhenium-SCT® (SCT= Skin Cancer Therapy)

GARCHING N. MUNICH, Germany, 13-May-2019 — /EPR HEALTHCARE NEWS/ — OncoBeta® GmbH, a commercial stage Medical Device Company specialized in innovative epidermal radioisotope therapies for Non-Melanocytic Skin Cancers (NMSCs), is pleased to announce that the interregional professional association for nuclear medicine in Hanau now offers the Rhenium-SCT ® (SCT= Skin Cancer Therapy) as the first treatment center in Germany.

With approximately 50.000 outpatient examinations annually, the interregional professional association for nuclear medicine Hanau is one of the biggest nuclear medicine service providers in Hesse. The offered services include a variety of different modern treatment and diagnostic methods which are state-of the art in science and technology.

“Offering NMSC skin cancer patients a highly efficient, painless, innovative therapy with excellent aesthetic results was the driving reason to establish this treatment method in our clinic,” says Dr. med. Lutz-Hendrik Holle, Medical Director of Nuclear Medicine in Hanau.

“We are delighted that our innovative skin cancer therapy Rhenium-SCT® is now being offered by the Nuclear Medicine in Hanau and we are looking forward to this collaboration”, states Shannon D. Brown III, CEO and Managing Director of OncoBeta® GmbH. “For us, this is an important step to offer the treatment method in addition to Italy, South Africa and Australia now also in Germany. In order to provide our treatment to as many skin cancer patients as possible, it is of course our goal to offer the availability of the therapy nationwide in Germany in the future.”

The global incidence of non-melanoma skin cancers has been drastically increasing over the past decades. Depending on the source, it is estimated that there are over 5 million non-melanoma skin cancer cases reported globally each year. In Germany the number of newly diagnosed patients is about 200,000 annually and it is assumed that this number increases within the next years. To serve the increasing medical need for innovative therapies in this field and to improve the quality of patients’ lives, OncoBeta® GmbH has developed its innovative Rhenium-SCT® which only require a single application, applied in one single session with excellent aesthetic outcomes.

If interested, patients and doctors can either contact the interregional professional association for nuclear medicine in Hanau directly or OncoBeta® GmbH.

SOURCE: EuropaWire

University of Pretoria Prof. Mike Sathekge is First in South Africa to Treat Non-Melanocytic Skin #Cancer Patients with Rhenium-SCT®

Garching n. Munich, Germany, 26-Nov-2018 — /EPR HEALTHCARE NEWS/ — OncoBeta® GmbH, a commercial stage Medical Device Company specialized in innovative epidermal radioisotope therapies for Non-Melanocytic Skin Cancers (NMSCs), announced today that Prof. Mike Sathekge from the University of Pretoria, Steve Biko Academic Hospital Nuclear Medical department and his clinical team has treated the first non-melanocytic skin cancer patients in South Africa with the innovative Rhenium-SCT® skin cancer treatment System. This next-generation radionuclide therapy technology applied by the nuclear medicine physician offers a new singles session, painless treatment for patients suffering from Basal Cell – and Squamous Cell Carcinomas (BCCs and SCCs).

The global incidence of non-melanoma skin cancers has drastically increased over the few past decades. Depending on the source, it is estimated that there are over 5 million non-melanoma skin cancer cases reported globally each year. Approximately 80% of non-melanoma skin cancers are basal cell carcinomas or squamous cell carcinomas with South Africa having one of the highest incidence rates in the world.

Prof. Mike Sathekge and his team at the University of Pretoria, Steve Biko Academic Hospital are focused on providing patients with personalized care using state-of-the-art technology that can deliver high-precision therapy and diagnostics with minimal side effects. The specialized team of experts in the nuclear medicine and medical physics, work closely with other disciplines within the university hospital, referring physicians, and other institutions, to ensure patients receive the best possible treatment for their specific type of cancer.

Martin Magwaza, CEO of Tautomer (PTY) LTD Oncobeta®’s distribution partner for the Rhenium-SCT® in Africa, is dedicated to providing South Africans with new innovative and effective therapies across the continent, coordinating with representatives from all levels of government and state for the health care landscape.

“The start of the Rhenium-SCT® in South Africa is a significant milestone in the international expansion of our ground-breaking treatment for BCCs and SCCs.,” said Shannon D. Brown III, CEO and Managing Director of OncoBeta® GmbH. “Our vision of bringing a revolutionary affordable skin cancer therapy to physicians and patients all over the world has come one step closer today”.

SOURCE: EuropaWire

Dr. Christina Marrongelli chosen by the World Congress on Pharmacology & Chemistry of Natural Compounds to moderate their 2018 conference in Paris

Dr. Christina Marrongelli chosen by the World Congress on Pharmacology & Chemistry of Natural Compounds to moderate their 2018 conference in Paris

Marrongelli selected for her expertise in Botanical Drug Development

LONDON, Jun-16-2018 — /EPR Healthcare News/ — As a leading expert in her field, Dr. Christina Marrongelli, PharmD has been chosen by the World Congress on Pharmacology & Chemistry of Natural Compounds to moderate their 2018 conference: Exploring New Trends & Innovations in Pharmacology and Natural Compounds. The conference is being held in Paris, France on June 18, 2018.

Dr. Marrongelli, who is an adjunct professor at the Medical University of South Carolina in the department of drug discovery and biomedical sciences will also present “Developing and Marketing Botanical Drugs in the United States”.

The United States, which has the largest pharmaceutical market in the world, demonstrates a strong demand for the use of botanicals as medicine. However, to date only two prescription botanical drugs are currently approved for use in the USA: Veregen® (sinecatechins) and Mytesi™ (crofelemer).

Marrongelli attributes this disconnect between supply and demand to hidden barriers. She notes that with the worldwide herbal drug market is expected to reach nearly $86.74 billion by 2022, businesses must identify and address these barriers so that heterogeneous botanical drug products can obtain the approvals necessary to meet the consumers growing expectations and demands for botanical medicines.

To further explain the barriers to regulation of botanicals, Marrongelli points to the Botanical Drug Development Guidance for Industry from the U.S. Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research (CDER) that was last updated in 2016. According to publication, regulation of botanicals in the U.S. is different from regulation in the rest of world. The U.S. does not have a separate regulatory category for traditional or herbal medicines: A botanical product may be classified as a food (including a dietary supplement), drug (including a biological drug), medical device, or cosmetic under the Federal Food, Drug, and Cosmetic Act (FD&C Act). Whether an article is a food, drug, medical device, or cosmetic depends in large part on its intended use.

To learn more about the issues and barriers to the development of botanical drugs, please contact Dr. Marrongelli at Marronge@musc.edu or DrM@pharmD.expert.

SOURCE: EuropaWire

Alliance Life Sciences to present expanded portfolio of pricing & market access services at the World Pharma Pricing and Market Access Congress 2018

SOMERSET, N.J. / LONDON, UK, 19-Mar-2018 — /EuropaWire/ — Alliance Life Sciences, a leading global life sciences consulting, pricing data and technology provider, announced that it is a sponsor at the World Pharma Pricing and Market Access Congress 2018 taking place March 20-21 in London, United Kingdom. As part of the largest pharmaceutical commercialization organization that services more than 300 of the industry’s top pharmaceutical, biotech and medical device companies, Alliance will present its expanded portfolio of pricing and market access services. The focus will be on pricing and reimbursement data managed by PricentricOne and pricing governance, reference and tender pricing software manage by PriceRight.

Now in its 12th year the World Pharma Pricing and Market Access Congress brings together the most innovative leaders and organizations to discuss all aspects of evidence, access and pricing. This year’s event will feature over 150 speakers and a greater range of topics being covered including Big Data & AI, rare diseases, advanced therapies and other emerging, innovative areas.

Alan Crowther, President of Global Markets noted “Alliance Life Sciences is pleased to be a sponsor of the World Pharma Pricing & Market Access congress, particularly this year. We have made a number of investments in our people and infrastructure in Europe. Our acquisition by Water Street partners in 2017 allowed us to offer enhancements in our Market Access offerings too. Europe continues to be our focus market and World Pharma Pricing & Market Access congress is a great venue to showcase our expended capabilities”.

SOURCE: EuropaWire

Prof. Lucien Abenhaim: There is an incredible challenge for the sustainability of health systems across the world

Prof. Lucien Abenhaim

LONDON, Dec-3-2017 — /EuropaWire/ — On December 5-6, 2017, 200 high-level experts from government, academia, biopharmaceutical developers and patient organisations convene in London (UK) to address the mounting challenge of accessibility and patient access to high-value, high-cost medical therapies.

The not-for-profit executive forum is organised by the London School of Hygiene and Tropical Medicine and analytica|LASER, a global research consultancy, to investigate topical questions around drug policy, global health systems sustainability and innovation funding through a combination of case studies, panel sessions, and roundtables. Delegations are registered from over 70 public and private organisations, including the World Health Organization, as well as health systems representatives from Belgium, England, Estonia, Croatia, France, Germany, Italy, Norway, Sweden, the United States and Wales. Multiple patient organisations support the meeting to ensure that the patient voice is reflected in all deliberations.

“Access to life-saving drugs is not a new challenge. The paradigm of accessibility was changed completely in the face of the deadly HIV epidemic. This time, however, accessibility concerns almost every domain of medicine such as cancer, auto-immune diseases and rare diseases. We must act now,” says Prof Peter Piot, Director of the London School of Hygiene & Tropical Medicine and former head of UNAIDS.

“There is an incredible challenge for the sustainability of health systems across the world”, says Prof. Lucien Abenhaim, London School of Hygiene & Tropical Medicine and Chairman of Analytica Laser. “It is critical that drug developers and health system engage on actionable proposals that address concerns around value, cost and overall access to innovation for the patients who need it. We are at an inflection point – the paradigms of the 1990’s can no longer guide us,” he adds.

The main plenary on December 6th features scheduled remarks by over a dozen authorities in the field, including Professor Baron Peter Piot (Director, London School of Hygiene & Tropical Medicine and former Head, UNAIDS), Dr. Olivier Brandicourt (Chief Executive Officer, Sanofi), Dr. Sarah Garner (World Health Organization), Prof. Dominique Le Guludec (President, French HAS), Sir Andrew Dillon (Chief Executive, National Institute for Health and Care Excellence UK) and Dr. Harold Paz (Chief Medical Officer, Aetna). The plenary is preceded by a scientific seminar on December 5th which gathers globally renowned academics to explore new frontiers on the methodology for the appraisal and valuation of high-value medicines.

Please contact the organisers for more information on the programming and media access, or refer to www.accessibility-symposium.org

SOURCE: EuropaWire

MEDLAB Series Europe, 13-15 Sep 2017, will cover Point of Care Testing (POCT), Histopathology, Lab Management, Microbiology and Haematology

Spain, 04-May-2017 — /EuropaWire/ — After many years of operating successful MEDLAB events around Africa, Asia and the Middle East, Informa Life Sciences Exhibitions, the worlds leading publishing and exhibitions company, has announced that the MEDLAB Series will be expanding its presence into Europe. Taking place at the Barcelona Congress Centre in Barcelona, Spain, from 13-15 September 2017, more than 3,000 industry professionals are expected to attend Europe’s leading event for laboratory management and diagnosis.

With the European In-Vitro Diagnostics (IVD) market expected to reach USD 15.5 billion by 2024, a platform such as MEDLAB presents a huge opportunity for global laboratory industry leaders, including manufacturers, dealers and distributors, to make inroads into the European market. Housing international exhibitors and covering 2,000 sqm of exhibition space, MEDLAB Europe will give visitors from across the world an opportunity to access cutting-edge laboratory products, next-generation technology, innovative services and world-class educational content.

According to Tom Coleman, Group Exhibition Director, MEDLAB Series: “The launch of MEDLAB Europe is in line with our global expansion strategy for our MEDLAB series of events. The increasing prevalence of chronic diseases, rising geriatric population coupled with the rising awareness towards early diagnosis, has positioned the European IVD and medical laboratory market as a critical market for manufacturers, services providers, and dealers and distributors from across the globe. MEDLAB Europe will generate substantial value for our customers and partners by driving further product innovation and deeper engagement in these specific markets.”

Over the four-day event, MEDLAB Europe will also offer a multi-disciplinary congress tackling current challenges and developments key to the European market, and leveraging the true potential of laboratory testing to dramatically improve patient outcomes across the continent.

The conference programme covers five main tracks including Point of Care Testing (POCT), Histopathology, Lab Management, Microbiology and Haematology. From new methods of effective lab management to the development of techniques in detecting diseases, the conferences will also review the expanding role of the laboratory medicine and discuss partnership between a clinician and a lab professional in providing delivery of care to every patient.

“The scientific programme at MEDLAB has been carefully designed in collaboration with some of the brightest minds in the medical laboratory industry in order to have a real impact on improving the health and wellbeing of patients across the region,” said Coleman.

For more information about the MEDLAB Europe Exhibition & Congress, please visit: www.medlabeurope.com.

SOURCE: EuropaWire

Multispectral Optoacoustic Tomography (MSOT) can now more reliably detect early stages of inflammation

GERMANY, Mar-30-2017 — /EPR HEALTHCARE NEWS/ — Ulcerative colitis and Crohn’s disease are the most common inflammatory bowel diseases (IBD). Globally, more than 4 million people suffer from recurring inflammation of the intestinal mucosa. To date, non-invasive methods have not been able to detect these forms of IBD reliably. Researchers at the University Hospital Erlangen (Germany) have now shown for the first time how Multispectral Optoacoustic Tomography (MSOT) can more reliably detect early stages of inflammation when compared with other non-invasive diagnostic methods. These results have recently been published in the New England Journal of Medicine.

Evaluating the inflammatory activity of the intestines early and accurately helps to prevent complications associated with IBD and guide an optimal therapy regime. Currently, doctors frequently rely on an invasive endoscopy procedure to assess the intestinal mucosa of patients with IBD. Additionally, non-invasive imaging methods are increasingly used in the clinic. For example, ultrasound allows clinicians to examine the structure, thickness and blood perfusion of the intestinal wall with changes in perfusion patterns indicating an onset of inflammation.

“With the MSOT procedure, we additionally use laser light, by which we can detect inflammation earlier than previously possible with ultrasound”, explains Prof. Dr. Maximilian Waldner, Professor at the University Hospital Erlangen. “The earlier we detect signs of an upcoming flare – i.e., a change in blood content – the quicker we can react and start a preventive treatment”. The MSOT technology was developed by iThera Medical in Munich, and was first used on IBD patients last year.

The researchers of the University Hospital Erlangen have recently published their results in the renowned New England Journal of Medicine. “We examined 108 patients with Crohn’s disease using the MSOT technology and compared the results to established non-invasive diagnostic procedures as well as endoscopy and histology”, says Prof. Waldner. “We were able to demonstrate that hemoglobin values in the tissue measured with MSOT indicate very accurately the inflammatory activity in the intestines. The method appears to be superior to other non-invasive procedures, as MSOT for the first time was able to detect even low levels of inflammation without having to perform endoscopy”.

Dr. Ferdinand Knieling, a physician at the University Hospital Erlangen, adds: “We are hoping that this principle can be applied to many applications and, in particular, also be used to enable safe evaluations of children and adolescents. With this new examination method, many of the currently invasive procedures might become obsolete.”

In optoacoustic imaging, the physician scans the intestines transabdominally through the skin, applying pulsed laser light in the near-infrared region. The energy of the light absorbed in tissue is converted into acoustic signals which are then acquired by an ultrasound detector. Christian Wiest, CEO of iThera Medical, comments: “MSOT is a new diagnostic imaging modality that can detect changes in tissue composition associated with a variety of diseases, without the use of contrast agents. The technology has already been applied in other clinical feasibility studies, e.g. for the detection of melanoma metastasis in sentinel lymph nodes or for the assessment of suspicious breast lesions”.

The results of the IBD study at the University Hospital Erlangen were published on March 30th 2017 in the New England Journal of Medicine (Volume 376, Issue 13, pg.1292-1294).

SOURCE: EuropaWire

Five Years After Iraq War’s Official End, a New York Community Is Still Healing

NEW YORK, NY, 2017-Jan-14 — /EPR HEALTHCARE NEWS/ — As the Iraq War’s official end in December 2011 marks its fifth anniversary, many questions remain on its fallouts. New York’s French-American community is one of them, as it remembers its blacklisting when France opted out of attacking Iraq.

Choosing diplomatic pressure rather than “shock and awe” ignited fury for many in New York. The call for anti-French boycotts resonated in tabloids as pictures of New Yorkers spilling wines in gutters vied with accusations of an ally’s betrayal and cowardice. Information can be found by searching for “New York’s anti-French boycotts and Iraq,” and “Freedom fries.”

How effective were the boycotts? “Very much so, even devastating,” says French consulate’s official physician and mental health coordinator at the time, Gérard Sunnen, MD, “the French-American community of New York was stunned by their virulence and persistence. Why, many wondered, did they materialize only in New York, in striking contrast to the rest of the country?”

“Targeted were all manner of French-American businesses, from Air France to bakeries, as rosters of marked companies circulated widely. Earliest felled were restaurants, whose sales plummeted by as much as half. Like dominoes, they closed their doors, dismissing their workers. Called by many the “consulate’s darkest hour,” it went on for interminable months, years, and still resonates today.”

“As layoffs mounted,” Dr. Sunnen added, “so did their mental health consequences, from all manner of stress reactions to self-destructive depressions. And workers suddenly out of work could not find employment because no one would take them. The consulate’s social services department work load soared to levels never attained before.”

Faced with this onslaught, the New York State Department of Health (NYSDOH) was repeatedly contacted to lend the community its medical and mental health assistance. In addition, New York State and city top officials were insistently asked to add their voice to call off the boycotts. All appeals remained unanswered and, for reasons of non-assistance and abandonment of responsibility, this matter was eventually reported and filed in New York and Federal courts.

Dr. Sunnen, who also cites his experience as a Vietnam-era U.S. veteran, concludes, “history needs constant reckoning, otherwise it can remain a fable. These events are now brought to light so that long-term allies can better understand and appreciate the meaning of their special relationship.”

References:

Gérard Sunnen, MD, www.triroc.com/sunnen
Supreme Court, State of New York, No. 102194/2012
U.S. District Court, Southern District of NY 12 Civ. 3417
U.S. Court of Appeals, 2nd Circuit 13-465cv
U.S. Health and Human Services (HHS) 1:13-cv-1242
New York State Division of Human Rights (NYSDHR) No. 10181422
National Transportation Safety Board (NTSB) No. DCA96MA070

Contact-Details: Gerard Sunnen, MD
gsunnen@aol.com
www.triroc.com/sunnen

Via EPR Network
More Healthcare press releases

New York’s Health Agency (NYSDOH) Cited in Iraq War’s Blowback

New York, NY, 2016-Dec-31 — /EPR HEALTHCARE NEWS/ — As the Iraq War’s official end on December 18, 2011 marks its fifth anniversary, many questions remain on its fallouts. New York’s French-American community is one of them, as it remembers its blacklisting when France opted out of attacking Iraq.

Choosing diplomatic pressure rather than “shock and awe” ignited fury for many in New York. The call for anti-French boycotts resonated in tabloids as pictures of New Yorkers spilling wines in gutters vied with accusations of an ally’s betrayal and cowardice. Information can be found by googling “New York’s French boycotts and Iraq,” and “Freedom fries.”

How effective were the boycotts? “Very much so, even devastating,” says French consulate’s official physician and mental health coordinator at the time, Gérard Sunnen, MD, “the French-American community of New York was stunned by their virulence. Why, many wondered, did they materialize only in New York, in striking contrast to the rest of the country?”

“Targeted were all manner of French-American businesses, from Air France to bakeries, as rosters of marked companies circulated widely. Earliest felled were restaurants, whose sales plummeted by as much as half. Like dominoes, they closed their doors, dismissing their workers. Called by many the “consulate’s darkest hour,” it went on for weeks, interminable months, and still resonates today.”

“As layoffs mounted,” Dr. Sunnen added, “so did their mental health consequences, from all manner of stress reactions to self-destructive depressions. And workers suddenly out of work could not find employment because no one would take them. The consulate’s social services department work load soared to levels never attained before.”

Faced with this onslaught, the New York State Department of Health (NYSDOH) was repeatedly contacted to lend the community its medical and mental health assistance. In addition, New York state and city top officials were insistently asked to add their voice to call off the boycotts. All appeals remained unanswered and, for reasons of non-assistance and abandonment of responsibility, this matter was eventually reported and filed in New York and Federal courts.

Dr. Sunnen, who also cites his experience as a Vietnam-era U.S. veteran, concludes, “history needs constant reckoning, otherwise it can remain a fable. These events are now brought to light so that long-term allies can better understand the meaning of their relationship.”

References:

Gérard Sunnen, MD: www.triroc.com/sunnen
Supreme Court, State of New York, No. 102194/2012
U.S. District Court, Southern District of NY 12 Civ. 3417
U.S. Court of Appeals, 2nd Circuit 13-465cv
U.S. Health and Human Services (HHS) 1:13-cv-1242
New York State Division of Human Rights (NYSDHR) No. 10181422
National Transportation Safety Board (NTSB) No. DCA96MA070

Contact-Details: Gerard Sunnen, MD

Via EPR Network
More Healthcare press releases

Global leader in serialization solutions Systech to attend the annual pharmaceutical congress CPhI Worldwide in Barcelona, 4 – 6 Oct 2016

systech_international_slogo_europawireBRUSSELS, 28-Sep-2016 — /EuropaWire/ — Systech International, a global leader in brand protection technologies, will partner with Sharp Packaging and SINEL SYSTEMS, part of the Autajon Group, at CPhI Worldwide, the annual pharmaceutical congress held in Barcelona from 4 – 6 October 2016.

Systech will be part of Sharp’s panel discussion addressing delegates on the theme of “Serialization: Optimizing Your Supply Chain Means Optimizing Your Partners.” The presentation will explore the critical path to supply chain readiness, risk assessment, benchmarking and serialization risk mitigation options. The briefing will take place in the Pharma Insight Briefing room on Tuesday, 4 October 2016 at 11:30am CEST.

Systech will also showcase its UniSeries™ serialization software offered as an integrated solution within Autajon’s exhibit booth #2P16 (Hall 2).

CPhI Worldwide, together with co-located events ICSE, InnoPack, P-MEC and FDF, will host more than 36,000 visiting pharma professionals from 4-6 October at the Fira Gran Via, Barcelona, Spain. More than 2,500 exhibitors from 150+ countries gather at the event to network and take advantage of more than 100 free industry seminars. Every sector of the pharmaceutical market is represented under one roof, this year in a new location in Barcelona.

With thousands of implementations across the globe, Systech is the world’s most trusted brand protection expert, and its UniSeries offering is the industry standard for serializing products. UniSeries is offered as an integrated solution with both Sharp Packaging and Autajon Group’s hardware. Systech’s patented, configurable software offers manufacturers the flexibility to adapt to new regulations without extensive reworking or revalidation, thereby reducing implementation, training and support costs.

“We are recognized as the world leader in serialization and brand protection,” states Manfred Voglmaier, Senior Director Sales Europe, Systech International. “With more than 30 years of experience in providing highly configurable solutions for serialization across a variety of industries ― along with our partners Sharp Packaging and Sinel ― gives us a unique insight for this panel.”

Systech’s products are in greater demand than ever before since it is estimated that over 15,000 production lines for prescription medication in Europe must be fitted with a serialization system over the next three years. The European Commission adopted a regulation on October 2, 2015, under which the serialization of prescription medicine packages will become mandatory in all EU countries by 2019.

Show exhibit hours are on Tuesday, 4 October – Thursday, 6 October. Systech representatives will be available in the Sharp Packaging booth #3L56 (Hall 3) during the event, as well as in the Autajon booth #2P16 (Hall 2). They will showcase Systech’s software solutions on sample packaging lines and via live demos throughout the event.

SOURCE: EuropaWire

Sway Medical’s app for sports concussion exam received European CE Mark as Medical Device

sway-concussiontest-is-a-validated-ios-app-based-concussion-management-system

TULSA, OK, 08-Sep-2016 — /EPR HEALTHCARE NEWS/ — Sway Medical is a US medical device company who’s software turns an iPhone or iPad into a mobile medical device that provides immediate medical grade, objective concussion measurement to medical professionals.

Sway Medical LLC (Sway) would like to announce its official availability in all European Union Countries. Sway was issued its CE Mark after being marketed in the United States and Canada for two years. This is significant because European sports organizations ranging from youth through pro level now have an affordable and convenient sideline assessment tool supporting concussion related medical decision making. Medical professionals and trained coaches can obtain a concussion assessment via an Apple mobile device (iPhone or iPad) and the Sway Balance™ System web-portal. Acute objective measurements are obtained by performing a 1.5 minute balance and reaction time test protocol. Licensed athletic trainers, physical therapists and athletic therapists are able to join physicians in acutely managing the underserved market of youth sports, ages six and older.

Concussion injuries are very common in sports, often going un-reported or ignored until the obvious symptoms have incapacitated the athlete or draws the attention of a parent or coach. Second Impact Syndrome (SIS) is a serious medical condition with published mortality rates of up to 50%. SIS occurs when an athlete returns to play while still recovering from an initial concussion injury. During this time, the brain is highly susceptible to additional injury and complications. The Sway Balance™ System is able to accurately assess and track the acute and chronic outcome related to an athlete’s balance, motion reaction time and concussion symptoms. The Sway Balance™ System provides a graphical representation comparing suspicious injury event tests against a pre-injury “normative” or baseline score. The comparison of event tests against an established baseline is a common measurement for traumatic brain injury diagnosis and recovery tracking.

The Sway Balance™ System is available for purchase by licensed medical professionals involved in school, occupational or sports medicine through www.swaymedical.com. Additional protocols are available to assess an individual’s “Fall Risk” or “Functional Status”.

SOURCE: EuropaWire

Healthcare Recruitment Expert Kevin Kirkpatrick Expands to Include More Than Just Physicians

Healthcare recruitment expert Kevin Kirkpatrick has averted his business focus from physicians to all members of the healthcare industry. While Avery Professional Group focused on building just teams of physicians, his new business TMA Healthcare Staffing will focus on building practices from the ground up.

TORONTO, March 2, 2015 — /EPR HEALTHCARE NEWS/ — Medical recruitment expert, Kevin Kirkpatrick has his sights set on more than physician recruitment. Branching off from the Avery Professional Group, Kirkpatrick has evolved into a full-fledged healthcare consulting firm, TMA Healthcare Staffing.

Instead of focusing on just placing physicians, TMA Healthcare Staffing will focus on the complete career span of all healthcare professionals, along with building practices and businesses from the ground up. TMA Healthcare Staffing offers potential clients expanded recruiting services and more administrative partnerships that can aid a healthcare professional at any point in their career.

“We are building off the previous experience of recruiting for hospitals such as the Peterborough Regional Health Centre and St Michael’s hospital in Toronto,” Kirkpatrick continued, “We believe there is a gap for organizations that can provide staffing services to the whole hospital and not just one area of it.”

About Kevin Kirkpatrick

Kevin Kirkpatrick is a seasoned professional with extensive experience in technology and healthcare recruitment. Combining both his academic credentials with his 15 years of recruiting and consulting experience, Kirkpatrick has the expertise to guarantee he is finding the best fit for an organization.

Kevin Kirkpatrick boasts 10 years in the healthcare recruiting industry, starting his own firm in 2008 and has developed invaluable relationships throughout the industry.

Contact

TMA Healthcare Staffing is currently working in a number of different cities both nationally and internationally to build accessible healthcare services for the communities.

For more information about recruiting or consulting services please contact:

Kevin Kirkpatrick
Managing Director/Founder
TMA Healthcare Staffing – A Donaldson & James affiliate.
Direct Toronto 1.905.419.1495 | toll free 1.855.568.7900 ext 842 | mobile 1.705.749.4853

Canada: Vancouver • Kelowna • Calgary • Edmonton • Winnipeg • London • Waterloo • Listowel • Hamilton • Mississauga • Toronto • Ottawa • Montreal • Halifax • St. John’s • UK | London • USA | Dallas • Houston • Austin • San Antonio• Charlotte

Medical Scribe Systems Named to Inc. 5000 List for Fastest Growing Private Companies in America

Medical Scribe Systems (MSS) is recognized as one of America’s fastest growing private companies by Inc. magazine. MSS has doubled its growth every year since 2011, while also improving customer satisfaction.

El Segundo, CA – 2014-8-21 — /EPR Healthcare News/ —  Medical Scribe Systems (MSS), the nation’s leading provider of scribe programs specializing in revenue cycle enhancement, has been chosen for Inc. 500|5000, an exclusive ranking of the nation’s fastest-growing private companies, published annually by Inc. magazine.

Medical Scribe Systems
Medical Scribe Systems

“We are thrilled to have made such a prestigious list alongside other successful, hardworking organizations,” says CEO Garret Erskine. “It is a testament to the effectiveness of the MSS scribe program in improving physician productivity, clinical documentation, and patient satisfaction.”

“The company was started by four physicians with a simple idea,” says Erskine. “By offloading the data entry component of their work, they quickly discovered how to stay focused on patient care by positively impacting patient interaction, clinical efficiency, and the quality of documentation in the Electronic Medical Record (EMR).”

The recognition of MSS as one of Inc.’s “Fastest Growing Private Companies” comes at a time as the Company has doubled its client base within the last year, while at the same time improving customer satisfaction.  The company now has over 2,000 scribes serving nearly 100 facilities across the nation.

“MSS is focused on data integrity, charge capture, and revenue cycle solutions ensuring that our scribe program actually pays for itself,” says Erskine.  “Our unique approach integrates the scribe program into the customer’s Revenue Cycle and Clinical Documentation Improvement processes.  MSS partners with customers to address data quality issues at the time and point of care.”

For more information about Medical Scribe Systems, visit http://www.medicalscribesystems.com or email info@scribesystems.com.

About Medical Scribe Systems

Medical Scribe Systems, the nation’s leading provider of scribe programs focusing on revenue cycle enhancement, provides real-time documentation services for emergency departments, outpatient clinics, and hospitalists nationwide. The company founders are board-certified physicians who started their first scribe program in 2003. Board members Dr. Mark Richmond and Fred Brown, the former Chairman of The Joint Commission, helped establish the first guidelines for scribe use and compliance.  Now in nearly 100 hospitals nationwide and employing more than 2,000 scribes, Medical Scribe Systems has doubled growth each year since 2011.

Contact:
David Fong
Director of Marketing
dfong@scribesystems.com
(877) 819-5900

###

Medical Scribe Systems has doubled its growth every year since 2011. Today, the company employs about 2,000 scribes in nearly 100 hospitals and outpatient clinics nationwide.
Medical Scribe Systems has doubled its growth every year since 2011. Today, the company employs about 2,000 scribes in nearly 100 hospitals and outpatient clinics nationwide.
MSS medical scribes are becoming a best practice for clinical documentation on the Electronic Medical Record. They improve revenue cycle by capturing all billable elements in real time.
MSS medical scribes are becoming a best practice for clinical documentation on the Electronic Medical Record. They improve revenue cycle by capturing all billable elements in real time.

Health Gorilla Releases Mobile Application for Doctors

Digital Health Leader Expands Marketplace Access with Mobility

SUNNYVALE, CA., 2014-8-20 — /EPR Healthcare News/ — Health Gorilla™, Inc., the first online healthcare marketplace to connect doctors and clinicians with over 9,000+ diagnostic labs and 35,000+ radiology centers, has announced today the release of Health Gorilla mobile.  Health Gorilla mobile provides access to the Health Gorilla Marketplace through the Apple® iPhone® and iPad™.

Today over 68% of doctors have standardized on the Apple platform to communicate with peers and patients. Doctors can now use their mobile devices to place electronic orders with Health Gorilla mobile to diagnostic labs, radiology centers, physical therapy, skilled nursing facilities (SNFs) and durable medical equipment (DME) and other medical providers nationwide with the ability to track and review the results instantly as they arrive.  Physicians can then forward electronic results within their practice or exchange them with peers and patients to streamline the process and improve quality of care.

According to a study published by the New England Journal of Medicine noted that approximately 59.3% of all of a primary care physician’s daily emails were for the interpretation of test results and 21.7% were responses to patients.  The use of email generally increases the risk for doctors and their patients as most email services are not HIPAA compliant.

Another study published in the Journal of the American Medical Association (JAMA) reported that researchers from the Michael E. DeBakey Veterans Affairs Medical Center in Houston conducted a survey of primary care practitioners and found that a third reported missing alerts about test results from an electronic health record notification system designed to inform them when a patient has abnormal test results.

Doctors are adopting iPad and iPhones as the platform of choice to communicate with peers and patients. Health Gorilla mobile integrated messaging greatly reduces the risk in communication between a doctor and their patients by offering a fully HIPAA compliant environment. Health Gorilla mobile enables a physician to securely and compliantly forward diagnostic test results, radiology images, admission and discharge summaries and other clinical documents to patients and care coordinators through secure messaging.

Benefits of Health Gorilla Mobile Include:

  • HIPAA compliant and ONC modular certified MU2 solution
  • Order in less time than it takes to use fax forms
  • Receive results faster wherever you are
  • Forward results to patients instantly
  • Immediately refer results to another doctor and send messages
  • Eliminate error prone paper processes
  • Mobile solution available at no charge for doctors and their teams

“We believe that the value proposition is clear and compelling for doctors and their teams.” said Steve Yaskin, Chief Executive Office, Health Gorilla, Inc.  “The existing process is heavily dependent on paper, fax and manual processing.  It is slow, cumbersome and prone to error.  Doctors can better manage their time, and the time of their administrative and care coordinating teams, by using the power of the marketplace through the Health Gorilla app.  Now they have one place to order from any diagnostic lab, radiology center, hospital, physical therapy, sleep center, SNF and other healthcare providers in the United States.  A doctor can start with us the first day and begin ordering through the marketplace immediately.  Health Gorilla is the first to deliver this capability.  No other vendor can provide this benefit.”

Health Gorilla mobile is available as an approved Apple® enterprise application and will be distributed to existing Health Gorilla Marketplace users via a secure link for the next month.  In September Health Gorilla mobile app will be available from the Apple® store and will be fully integrated with the Apple® Health app upon its release.

About Health Gorilla
Health Gorilla™ is the first online healthcare marketplace to connect all doctors and clinicians with over 9,000+ diagnostic labs and 35,000+ radiology centers.  Doctors and their teams can instantly place orders, get results, and completely eliminate paper faxes. Uniquely, our HIPAA compliant and ONC modular certified MU2 solution is available immediately at absolutely no charge for doctors and clinicians.

Watch our 2 minute video Intro to Health Gorilla: http://youtu.be/6Luo5eNG8-s
Tweet: https://www.twitter.com/healthgorilla
Facebook: https://www.facebook.com/healthgorilla
LinkedIn: https://www.linkedin.com/company/2542523?
Sign-up for our Newsletter at the bottom of homepage:
http://www.healthgorilla.com

Contacts

For additional information contact Joe Austin via jaustin@theventanagroup.com or call 818-332-6166.

Health Gorilla™ is a trademark of Health Gorilla, Inc.
Apple®, iPhone®, iPad mini™ are trademarks of Apple, Inc.

Health Gorilla Releases Mobile Application for Doctors
Health Gorilla Releases Mobile Application for Doctors

The End of Alzheimer’s? A revolutionary scientific advance to the cure

Interface Dynamics Control Corporation (IDCC) has completed the first phase of its decade-long Advanced Therapeutic Interventions Project, with the result that a new approach to arresting and curing Alzheimer’s disease and the other neurodegenerative diseases has been produced and verified. IDCC is now launching the Project’s second phase, which will validate the first phase findings.

Alzheimer’s disease is the sixth leading cause of death in the United States, with more than 5.1 million Americans currently affected. The direct cost of Alzheimer’s is greater than $200 billion annually, a number expected reach between $1.2 and $1.5 trillion by 2050. Indirect costs are substantial: more than 15 million caregivers delivered some 17.5 billion hours of unpaid care valued at more than $200 billion.

IDCC has discovered the mechanism of and means to control the protein misfolding, abnormal aggregation, and degradation processes associated with the degenerative and prion diseases. That mechanism is also implicated in the failure to clear toxic intracellular proteins and in the dysfunction of apoptotic (programmed cell death) pathways. It underlies the adverse functions of the neuroglia (glial cells), including microglia, which provide immune defense to the central nervous system (CNS) and maintain homeostasis and protection for neurons in the brain and the peripheral nervous system.

The process of neurodegeneration has not been understood previously, which has precluded the production of any arresting or curative procedures or drugs. The Project’s findings, however, should lead to the realization of a new class of curative procedures and pharmaceuticals which can be engaged to defeat the disease-initiating neurodegenerative insult, thereby introducing the possibility of preventing these devastating diseases. There are direct implications for the human cancers, but verification of those implications must await further experiments.

The first major activity under the Project’s second phase will be the production of a new class of active imaging system. That system will be utilized to demonstrate the activities and accessible control points of the process pathways which, when certain abnormal events occur, trigger the incipient causal mechanisms of disease. The Project is currently developing the staff and capitalization required for execution of its second phase.

About IDCC 
IDCC was founded thirteen years ago to produce definitive solutions to seemingly intractable problems of social and technological significance. It is privately held and maintains its projects and client identities in strict confidence unless and until information releases are authorized by competent authority.

Contact Details: Peter W. Atkinson
IDCC
4655 Logsdon Drive
Annandale, VA 22003-3564 USA
+1.703.879.7065
Peter@InterfaceDynamicsControl.com

Via EPR Network
More Healthcare press releases

Save Money on the Cost of a Brand New Bike in Time for National Bike Week 2013

As the nation gears up for National Bike Week 2013, leading health cash plan provider UK Healthcare offers discounts for policy holders on the cost of a brand new bike.

As National Bike Week returns for another year, a leading health cash plan provider UK Healthcare, is reminding policy holders that they can save money on the cost of a brand new bike thanks to their plan.

National Bike Week 2013 runs from Saturday 15 June until Sunday 23 June, with cycling events taking place throughout the UK. From local authorities and community groups to charities and cycling groups, bike fans up and down the country will take part fun cycles, city rides, heritage cycles, bike races and much more. There is an event for everybody young and old, and all are encouraged to get involved with a local event and rediscover the love of cycling.

Whether commuting or enjoying a weekend trip, cycling is a fantastic way to get some exercise and enjoy some fresh air.

In addition to providing comprehensive personal and corporate health cash plans, UK Healthcare champion a healthy active lifestyle, and policy holders can take advantage of a range of special offers, which includes discounts off a selected range of brand new bikes from Halfords.

With personal and corporate health cash plans from UK Healthcare, policy holders can claim back the cash spent on a wide range of medical services from dental checkups and eye tests to hospital stays, health screenings and much more. Cover is available from as little as 28p per day and 100% cash back is available on a wide variety of treatments and prescriptions up to generous policy limits.

For more information about the many benefits of a personal or corporate health cash plan, or the special offers available to the policy holder, visit the official UK Healthcare website today.

Via EPR Network
More Healthcare press releases